Providing relief from treatment-resistant depression

Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.

Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate through funding granted by the BioInovation institute (Novo Nordisk Foundation) and plan to begin first-in-human trials by 2023.

The company has identified and patented a new class of proprietary ligands that share a pharmacological profile with psilocybin, which has shown promising clinical results in the treatment of depression.

Lophora is currently focusing on Treatment-Resistant Depression, but clinical data suggests that the new drug class will be applicable to the treatment of other CNS disorders including anxiety, PTSD and substance abuse.

Lophora holds a unique position in the market for anti-depressant therapies of the future. The company seeks to mature lead-candidate LPH-5 through pre-clinical operations, toward IND status by the end of 2022.

Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards Psychedelic-assisted therapy as a treatment for CNS disorders.

Why a novel treatment paradigm?

Current Treatment Paradigm Novel Treatment Paradigm
Patients take their medicine daily for years.
Patients participate in a single hallucinogenic treatment session lasting several hours.
Patients take their medicine at home.
Patients are treated in a clinic under supervision of trained therapists.
Current medicines have slow onset of action - typically several weeks.
Relief from depressive symptoms are apparent within days following single treatment
Current medicines are associated with serious side effects - such as sexual dysfunction, weight gain and insomnia.
Hallucinogenic treatment session may be challenging to some patients

Get In Touch

Lophora is located at the BioInnovation Institute at COBIS Science Park in Copenhagen, Denmark.

Contact: /+45 51 86 84 82